公开(公告)号：US20200263261A1

公开(公告)日：2020-08-20

申请号：US16867125

申请日：2020-05-05

Applicant: Genentech, Inc.

Inventor： Yinghui GUAN ,  Yasin SENBABAOGLU ,  Shannon TURLEY ,  Yulei WANG

IPC: C12Q1/6886 ,  G01N33/574 ,  A61K39/395

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), methods for selecting a therapy for an individual having cancer, methods of treating an individual having cancer, methods for assessing a response or monitoring the response of an individual to treatment with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), and related kits, anti-cancer therapies, and uses.

公开(公告)号：US20240011098A1

公开(公告)日：2024-01-11

申请号：US17901481

申请日：2022-09-01

Applicant: Genentech, Inc.

Inventor： Yinghui GUAN ,  Yasin SENBABAOGLU ,  Shannon TURLEY ,  Yulei WANG

IPC: C12Q1/6886 ,  A61K39/395 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K39/39558 ,  G01N33/57488 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), methods for selecting a therapy for an individual having cancer, methods of treating an individual having cancer, methods for assessing a response or monitoring the response of an individual to treatment with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), and related kits, anti-cancer therapies, and uses.

公开(公告)号：US20250054631A1

公开(公告)日：2025-02-13

申请号：US18929486

申请日：2024-10-28

Applicant: Genentech, Inc.

Inventor： Yinghui GUAN ,  Shan LU ,  Yulei WANG ,  Alexander ABBAS

IPC: G16H50/20 ,  G16H20/17 ,  G16H30/40 ,  G16H50/70

Abstract: A method for hepatocellular carcinoma (HCC) subtype classification and treatment may include identifying, for a liver epithelial cell lineage, one or more features associated with the liver epithelial cell lineage. The one or more features may be designated as representative of a molecular subtype associated with hepatocellular carcinoma (HCC) such as, for example, a cholangio-like subtype, a hepatocyte-like subtype, or a progenitor-like subtype. A patient may be determined to exhibit the molecular subtype if these features are detected within the tumor sample of the patient. Moreover, treatment for the patient may be determined based on the molecular subtype exhibited by the patient. For example, treatment for the patient may include additional therapies, such as an GPC3/CD3 bi-specific antibody, to overcome subtype-specific resistance to combination immunotherapy associated with the progenitor-like subtype. Related systems and computer program products are also provided.